HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties.

2H-1-Benzopyran-2-one, 3-(3H-imidazo[4,5-c]pyridin-2-yl)-6-methyl- is a first-in-class JMJD6 inhibitor and was shown to be able to suppress JMJD6-dependent cancer cell proliferation including cervical and liver cancer cells.

Exherin (ADH-1) is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities.